MAS CELL PRODUCT MANUFACTURER REGISTRATION DUE BY LATE NOVEMBER, IND/BLA IN 18 MONTHS, FDA SAYS; SHORT-TERM DATA GENERALLY ACCEPTABLE TO SHOW EFFICACY
This article was originally published in The Gray Sheet
Executive Summary
Manufacturers of autologous cell products for structural repair must register as drug manufacturers with FDA by the end of November, according to the agency's plan for regulating the products. The policy covers products comprised of living autologous cells manipulated ex vivo and intended for structural repair or reconstruction (MAS cells).
You may also be interested in...
Colorado Price Cap Plan For Enbrel Draws Amgen Lawsuit; Cosentyx, Stelara ‘Affordability’ Reviews Pending
However, the state's recently formed prescription drug affordability board found Gilead’s Genvoya and Vertex’s Trikafta to be affordable.
Biden Administration Is Setting An Example For Safe AI Use In Federal Organizations
A new memorandum by the Director of the Office of Management and Budget initiated a government-wide policy that will appoint AI officers to all agencies to address risks for AI use and serve as an example for greater AI adoption.
US FDA Drugs Center Ready To Break Down Silos On Regulatory Innovation
CDER Director Cavazzoni is promising to increase coordination and collaboration to accelerate broader adoption of innovative clinical trial designs and other approaches to speed drug development. A new "Quantitative Medicine Center of Excellence" illustrates the approach.